Class-and isoform-specific HDAC inhibitors and uses thereof
US10059657B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jan 5, 2017 |
| Grant date | Aug 28, 2018 |
| Priority date | — |
| Expiry date | Jan 5, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D401/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
HDAC inhibitors of the general formula (I) and (II) and pharmaceutically acceptable salts thereof, as described herein, are useful as inhibitors of histone deacetylases or other deacetylases, and thus are useful for the treatment of various diseases and disorders associated with acetylase/deacetylase activity as described herein (e.g., cancer). In certain embodiments, the compounds of the invention selectively target either a class or isoform of the HDAC family. Another aspect of the invention provides an assay for determining the inhibitory effect of a test compound on an HDAC protein comprising: incubating the HDAC protein with a substrate of general formula (IIIc) in the presence of a test compound; and determining the activity of the HDAC protein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.